WilmerHale Advises Infinity Pharmaceuticals in Definitive Merger Agreement with MEI Pharma

WilmerHale Advises Infinity Pharmaceuticals in Definitive Merger Agreement with MEI Pharma

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Critical industry insight and formidable strength across key practices.

On February 23, 2023, Infinity Pharmaceuticals and MEI Pharma announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a company combining the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates. Headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals is a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate. MEI Pharma is a clinical-stage pharmaceutical company focused on advancing new therapies for cancer. 

The WilmerHale team advising Infinity Pharmaceuticals included Hal Leibowitz, Michael Gilligan, Cynthia Mazareas and Judd Abramson. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel